Evidence mapPaperPMID 26931809Full record

ReviewCold Spring Harbor perspectives in medicine2016

Metformin: A Hopeful Promise in Aging Research.

Marta G Novelle, Ahmed Ali, Carlos Diéguez, Michel Bernier, Rafael de Cabo

Open access · bronzeAbstract readReview
In one paragraph

Review in Cold Spring Harbor perspectives in medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers.

0numbers the graph read from it
0cells of the map it votes in
93citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

93 citing papers in PubMed, 166 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Astrocytes in aging.Neuron · 2025
    Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review

33 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Marta G NovelleTranslational Gerontology Branch, National Institute on Aging, NIH, Baltimore, Maryland 21224 Research Center of Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela 15706, Spain.
Ahmed AliTranslational Gerontology Branch, National Institute on Aging, NIH, Baltimore, Maryland 21224.
Carlos DiéguezCIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela 15706, Spain.
Michel BernierTranslational Gerontology Branch, National Institute on Aging, NIH, Baltimore, Maryland 21224.
Rafael de CaboTranslational Gerontology Branch, National Institute on Aging, NIH, Baltimore, Maryland 21224.
National Institute on Aging · USCentro de Investigación Biomédica en Red · ESInstituto de Investigación Sanitaria de Santiago · ES

Funding

Aging Intervention ProgramZIAAG000363 · NATIONAL INSTITUTE ON AGING · 2025 to 2025
$912k
Calorie restriction and agingZIAAG000368 · NATIONAL INSTITUTE ON AGING · 2025 to 2025
$444k
Intramural NIH HHS
6 · The paper itself

Abstract

Even though the inevitable process of aging by itself cannot be considered a disease, it is directly linked to life span and is the driving force behind all age-related diseases. It is an undisputable fact that age-associated diseases are among the leading causes of death in the world, primarily in industrialized countries. During the last several years, an intensive search of antiaging treatments has led to the discovery of a variety of drugs that promote health span and/or life extension. The biguanide compound metformin is widely used for treating people with type 2 diabetes and appears to show protection against cancer, inflammation, and age-related pathologies. Here, we summarize the recent developments about metformin use in translational aging research and discuss its role as a potential geroprotector.

Indexed as

AgingHumansLife ExpectancyMetforminTranslational Research, BiomedicalMetformin

Identifiers

PMID26931809
PMCPMC4772077
OpenAlexW2289120809

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.